SCHEMBL14095965

SCHEMBL14095965

CCCCOC(=O)c1ccc(NC(=S)NC(=O)c2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.63
MAPT P10636 4/20 0.63
GAA P10253 2/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
SMN1; SMN2 Q16637 6/20 0.61
HPGD P15428 1/20 0.61
RECQL P46063 1/20 0.61
EPHX1 P07099 2/20 0.60
MAPK1 P28482 1/20 0.58
POLB P06746 1/20 0.58
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
RNASEL Q05823 1/20 0.56
LMNA P02545 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14095969 0.92 ALDH1A1 (0.61) ALDH1A1MAPTGAACYP1A2CYP2C9
SCHEMBL14095980 0.91 ALDH1A1 (0.64) ALDH1A1MAPTGAACYP1A2CYP2C9
SCHEMBL14137019 0.89 CYP1A2 (0.65) ALDH1A1MAPTGAACYP1A2CYP2C9
SCHEMBL14095985 0.89 KMT2A (0.64) ALDH1A1MAPTGAACYP1A2CYP2C9
SCHEMBL14095976 0.88 ALDH1A1 (0.61) ALDH1A1MAPTGAACYP1A2CYP2C9
SCHEMBL2864417 0.88 NPC1 (0.63) ALDH1A1MAPTGAACYP1A2CYP2C9
SCHEMBL14096379 0.88 ALDH1A1 (0.78) ALDH1A1MAPTGAASMN1; SMN2HPGD
SCHEMBL13956729 0.86 MAPT (0.60) ALDH1A1MAPTGAACYP1A2CYP2C9
SCHEMBL14095996 0.85 RAB9A (0.64) ALDH1A1MAPTGAACYP1A2CYP2C9
SCHEMBL4361509 0.85 HPGD (0.75) ALDH1A1MAPTGAACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv RNASE1, SARS1, EIF2AK2 ALDH1A1 2930/4885MAPT 4038/4885GAA 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.